Introduction
5-Fluorouracil (5-FU) has been widely used clinically in the treatment of solid tumors since it was first synthesized in 1957 [1] . It is thought to be one of the key drugs for chemotherapy in gastric cancer, and several analogues have been developed. The mechanism of action of 5-FU has been explained in terms of the inhibition of thymidylate synthase (TS) by the active metabolite 5-fluorodeoxyuridine monophosphate (FdUMP), or the incorporation of fluorouridine 5Ј-triphosphate (FUTP) into RNA, resulting in the distortion of gene expression. In continuous infusion and oral administration of 5-FU and its analogues, inhibition of DNA synthesis is thought to be the predominant mechanism of action [2] . Tumor TS activity has been reported to correlate with the efficacy of 5-FU in preclinical and clinical experiments [3] [4] [5] [6] . In addition to its role in pyrimidine nucleotide synthesis, TS is also associated with cellular proliferation. TS protein expression in the primary tumor was reportedly found to be an independent prognostic marker in rectal cancer [7] .
Thymidine phosphorylase (TP) is known to have a high homology with platelet-derived endothelial growth factor (PD-ECGF); have activity as an angiogenesis-inducing factor [8] ; and to be related to tumor growth/progress in gastric [9] [10] [11] , breast [12] , and colorectal cancers [13] . Furthermore, TP is reportedly an enzyme that converts capecitabine and its intermediate metabolite, 5Ј-deoxy-5-fluorouridine (5Ј-DFUR) to 5-FU [14] . It is also reported that TP activity in tumor tissue correlates with 5-FU concentration in tumor tissue following capecitabine administration [15] , and with tumor sensitivity to capecitabine and 5Ј-DFUR [16, 17] .
Recently, it has been found that dihydropyrimidine dehydrogenase (DPD), an initial and rate-limiting catabolic enzyme, has significance for the pharmacokinetics and toxicity of 5-FU [18, 19] , and it is reported that patients with DPD deficiency show severe toxicity to 5-FU administration [20] . It is also reported that, in tumors with high DPD activity, 5-FU decomposition is accelerated, resulting in resistance to 5-FU [3, 21] .
We have previously investigated the role of TS and DPD in tumor sensitivity to 5-FU, and reported an inverse correlation between DPD activity and 5-FU sensitivity [22] . We have also investigated the correlation between TP and DPD protein level, determined by enzyme-linked immunosorbent assay (ELISA) and 5Ј-DFUR sensitivity, and reported that the TP/DPD ratio is important for predicting 5Ј-DFUR sensitivity [23] . The present study was designed to further elucidate the role of TS, DPD, and TP in tumor progression and sensitivity to 5-FU. We compared TS and DPD enzyme activities and TP protein level with clinicopathologic factors, postoperative survival period, and in-vitro tumor sensitivity to 5-FU. Furthermore, we also investigated the role of DPD inhibitors in the enhancement of the antitumor effect of 5-FU, using nude mouse transplantable gastric cancer xenografts.
Subjects, materials, and methods

Patients
We obtained a total of 275 fresh human gastric cancer samples from the surgically resected tumors of 275 patients who underwent gastrectomy at the First Department of Surgery, Iwate Medical University, from April 1997 to December 2001. Tumor tissue and adjacent normal tissue were obtained from surgically resected samples and stored at Ϫ80°C until assayed. Patient characteristics, determined according to the Japanese classification of gastric carcinoma [24] , are shown in Table 1 .
Of these 275 patients, 165 did not receive any chemotherapy after surgery, 74 patients received 5-FU-based adjuvant chemotherapy (27 received oral uracil plus tegafur [UFT]; 29, oral 5Ј-DFUR; 7, low-dose cisplatin [CDDP] with 5-FU; 7, oral 5-FU; 3, continuous infusion of 5-FU; and 1, methotrexate with 5-FU), 20 patients received intraperitoneal CDDP with continuous infusion of 5-FU, 13 patients received 1 M tegafur -0.4M 5-chloro-2,4-dihydroxypyridine -1 M potassium oxonate (S-1) with or without CDDP, and 3 patients received irinotecan. The treatment regimen was selected by the physician in charge. All patients gave their written informed consent to enter the study and the experiments were carried out after the protocols were approved by the local ethics committee.
Animals
We purchased male BALB/cA nude mice (age, 4 weeks; weight, 18-20 g) from Clea Japan (Tokyo, Japan); they were fed a sterilized pellet diet and received autoclaved water ad libitum. The animals were housed under specific pathogen-free conditions with a laminar flow rack.
Tumors
We obtained three human gastric cancer cell lines (GCIY, GT3TKB, and MKN-74) from the Riken Cell Bank (The Institute of Physical and Chemical Research, Saitama, Japan) and cultured these cell lines in RPMI-1640 medium containing 10% fetal bovine serum (GIBCO/BRL, Rockville, MD, USA) at 37°C in 5% CO 2 . Cells in the logarithmic growth phase were detached, and 1 ϫ 10 6 cells were transplanted subcutaneously into the dorsal flank of each mouse with a trocar needle. When the tumor volume reached 100 mm 3 , the mice were killed, and tumors were harvested for further Diff., Differentiated; undiff., undifferentiated a Clinicopathologic factors were determined according to the General rules for gastric cancer study (2nd English edition) [24] experiments. TS activities in MKN-74, GCIY, and GT3TKB were 0.094, 0.311, and 2.621 pmol/mg protein, respectively. Similarly, DPD activities in MKN-74, GCIY, and GT3TKB were 6.0, 277.8, and 287.8pmol/ mg per min, respectively [25] .
Drugs
We obtained 5-FU from Kyowa Hakko Kogyo (Tokyo, Japan) and it was dissolved in 0.9% NaCl solution.
We also obtained tegafur (FT), 5-chloro-2,4-dihydroxypyridine (CDHP), potassium oxonate (Oxo), and uracil from Taiho Pharmaceutical (Tokyo, Japan 
TS activity
We determined TS activity in 130 samples according to the method of Spears et al. [27] , with minor modifications as described previously [22] . Enzyme solution was obtained from tumor tissue and then incubated with 0.6M NH 4 HCO 3 (pH 8.0), 0.1M 2-mercaptoethanol, 0.1M NaF, and 15mM 5-cytidine monophosphate at 25°C for 3h. The solution was further incubated with H] FdUMP, 2mM tetrahydrofolate, 16mM ascorbate, 9mM formaldehyde, 15mM 5-cytidine monophosphate, 20mM 2-mercaptoethanol, and 100 mM NaF at 30°C for 20min and then centrifuged at 2000g for 5min. Trichloroacetic acid was added to the pellet, and the tritiated water formed during the incubation was then quantified by liquid scintillation counter. We expressed TS activity as pmol/mg protein.
DPD activity
We measured DPD activity in 140 samples according to the procedures of Takechi et al. [28] , with minor modifications as described previously [22] . Briefly, enzyme solution obtained from tumor was incubated with reaction mixture containing 2mM dithiothreitol (DTT), 5mM MgCl 2 , 20 µM [6-14 C] FU (56nCi), and 100 µM NADPH at 37°C for 10 min or 30min. The reaction was stopped by boiling, and the solution was centrifuged at 1500 g for 10 min; the supernatant was then incubated with 0.36M KOH at room temperature for 30 min. The solution was then mixed with 0.36M HClO 4 and centrifuged at 1500 g for 10min. An aliquot of supernatant was applied to a thin-layer chromatography plate (silica gel 60 F254; Merck, Darmstadt, Germany), which was then developed with a mixture of 99% ethanol and 1M ammonium acetate (5:1, v/v). The plate was then read by an imaging analyzer (Bio-Rad, Richmond, CA, USA) and the densities of 5-FU and the degradation products were calculated. We expressed DPD activity as pmol/mg protein per min.
TP protein levels
We assayed the TP protein level in 157 samples with an ELISA system, as described previously [23] . We expressed the TP enzyme level as U/mg protein, where one unit (U) of TP is an amount equivalent to 1µg of 5-FU produced in an hour.
In-vitro drug sensitivity testing of freshly obtained gastric cancer samples
When the resected sample size was large enough, we also determined the sensitivity of the freshly resected tumor to 5-FU by carrying out an ATP assay with serum-free culture developed at our department [29] . Briefly, each tumor sample was sliced into small fragments and digested enzymatically to obtain a suspension of single cells. Cells at a concentration of 2 ϫ 10 4 cells/180µl were dispensed onto a 96-well microtiter plate for a total of 3 to 6 wells in each drug-untreated control group and drug-treated group. In drug-treated groups, 20µl of 5-FU was added at final concentrations of 50 µg/ml. These concentrations correspond to the peak plasma concentration following the administration of a standard dose. Then the plate was incubated for 72h in 5% CO 2 at 37°C. Cell viability was determined by measuring intracellular ATP content by the bioluminescence method. We determined the assay results to be evaluable if, after incubation, the ATP level in the control group was more than 2.0nM. The relative tumor growth inhibition rate (IR%) was calculated as follows: (1 Ϫ average ATP level in the drug-treated group/average ATP level in the control group) ϫ 100.
Antitumor activity of 5-FU in human gastric cancer xenografts
We inoculated tumor tissue fragments, each measuring approximately 10mm 3 , into the dorsal flank of each nude mouse, using a trocar needle, and measured the tumor volume ([major axis] ϫ [minor axis] 2 ϫ 1/2) twice weekly. When tumor volume in the nude mice reached approximately 100 mm 3 , we allocated the tumor-bearing mice randomly to groups of six animals each. 5-FU was administered intraperitoneally at a dose of 50mg/kg three times every 4 days. S-1 and UFT were administered orally at a dose of 10 mg/kg or 24mg/kg, respectively, once daily for 9 consecutive days [26] . The control group received 0.5% (w/v) HPMC solution orally once daily for 9 consecutive days. Tumor volume was measured every 2 days after drug treatment. We calculated the relative tumor volume (RTV) as follows: (mean tumor volume during treatment)/(mean tumor volume at the start of treatment), and evaluated the antitumor effects by calculating the tumor growth inhibition rate (TGIR%). TGIR % ϭ (1 Ϫ mean RTV of treatment group/mean RTV of untreated group) ϫ 100.
Statistical analysis
Statistical analysis was performed on a personal computer with Stat View ver. 5.0 software (SAS Institute, Cary, NC, USA). Statistical differences between two groups were evaluated using the Mann-Whitney test, and for three or more groups, using the Kruskal-Wallis test. To evaluate the correlation between two variables, linear regression was performed and Spearman's rank correlation coefficient was calculated. The 2 test was used for testing the correlation between enzyme levels and tumor stage. The survival rate was calculated by the Kaplan-Meier method and statistical analysis was performed by using the log rank test. Cox proportional hazards analysis was used to estimate the prognostic value of various factors. A P value of less than 0.05 was considered to be statistically significant. Table 2) . DPD showed no correlation with clinicopathologic factors. TS showed a significant correlation only with venous invasion (P ϭ 0.0357). However, TP levels were significantly correlated with the depth of tumor invasion (P ϭ 0.0173) and with lymphatic invasion (P Ͻ 0.0001) and venous invasion (P Ͻ 0.0001).
Results
TS, DPD, and TP in primary human gastric cancer
Correlation between enzyme activities and sensitivity to 5-FU
In 94 of the 275 samples, a relatively large amount of tumor was obtained and in-vitro drug sensitivity testing * P Ͻ 0.0001 Diff., Differentiated; undiff., undifferentiated; TS, thymidy late synthase; DPD, dihydropyrimidine dehydrogenase; TP, thymidine phosphorylase a Clinicopathologic factors were determined according to the General rules for gastric cancer study (2nd English edition) [24] was performed. Of these 94 samples, tumor sensitivity to 5-FU was evaluable in 79 samples (84%). In these samples, correlation between sensitivity to 5-FU and enzyme activities or protein level was investigated (Fig. 1) .
With regard to 5-FU sensitivity, no significant correlation was obtained between tumor sensitivity and TS activity or TP protein level. However, tumors with high DPD activity were relatively resistant to 5-FU. There was a weak inverse correlation between DPD activity and sensitivity to 5-FU (r s ϭ Ϫ0.351; P ϭ 0.0170) (Fig. 1) .
Patient survival according to TS, DPD, and TP
Overall survival after gastrectomy was retrospectively evaluated according to the levels of these enzyme activities and protein level. Cutoff levels of TS, DPD, and TP were set at the median values. Neither TS nor TP were predictive of the survival time of the patients, when we examined all the patients together. However, overall survival was significantly worse for the 70 patients with high DPD activity than for the 70 with low DPD activity (Fig. 2) .
In a subset analysis of those who had no adjuvant chemotherapy after surgery, overall survival was worse for the 16 patients with high TS activity than for the 30 with low TS activity. DPD (n ϭ 44) and TP (n ϭ 50) had no impact on the survival of patients without adjuvant chemotherapy (Fig. 3) .
Similarly, overall survival was evaluated according to TS, DPD, and TP in a subset analysis of those who received 5-FU-based adjuvant chemotherapy after surgery. Overall survival was worse for the 29 patients with high DPD activity than for the 34 with low DPD activity (Fig. 4) .
In order to clarify the role of TS, DPD, and TP in patient survival, we performed multivariate analysis, using Cox's proportional hazard model, that included sex, age, peritoneal metastasis, hepatic metastasis, depth of tumor invasion, lymph node metastasis, adjuvant chemotherapy, TS and DPD activities, and TP protein level. It was found that TS activity, as well as peritoneal metastasis, hepatic metastasis, and lymph node metastasis, were independent prognostic factors in patients with gastric cancer (Table 3) .
Antitumor activities of 5-FU, UFT, and S-1 against human gastric cancer xenografts
Antitumor activities, expressed as maximum TGIR, are shown in Fig. 5 . There was no significant difference in antitumor activity among the drugs in MKN-74, in which both TS and DPD activities were low. However, antitumor activity was significantly higher in animals treated with S-1 than in those treated with 5-FU or UFT in GCIY and GT3TKB, which had high DPD activities.
Discussion
TS is thought to be a key enzyme in the inhibition of DNA synthesis caused by 5-FU treatment. The anabolism of 5-FU in cancer cells results in the synthesis of FdUMP, which inhibits DNA synthesis by forming a tight covalent complex with TS and 5,10-CH 2 FH 4 [2] . Several investigators have reported that cell lines with acquired resistance to 5-FU show increased expression of TS [30] . Furthermore, a strong correlation has been reported between TS activity and cellular sensitivity to 5-FU in preclinical and clinical experiments [3] [4] [5] [6] . Recently, it has been reported that polymorphism of the tandem repeat sequence in the TS promoter strongly correlates with responsiveness and patient survival after 5-FU based chemotherapy [31, 32] . However, in the present study, no correlation was found between TS activity and in-vitro sensitivity to 5-FU in clinical samples of primary gastric cancer. In addition, we failed to obtain a significant difference in overall survival according to the TS level in patients who received 5-FU-based adjuvant chemotherapy. Although several investigators have demonstrated the significance of TS, the role of TS in sensitivity to 5-FU is still controversial.
No correlation between TS activity and 5-FU sensitivity was documented in several reports [33, 34] . These reports indicated that other markers, such as DPD, multidrug resistance-associated proteins, and cell cycle parameters, more strongly correlated with sensitivity to 5-FU than TS activity. Clinically, Findlay et al. [34] and Etienne et al. [21, 35] also reported no correlation between TS expression and response to 5-FU in patients with colorectal cancer and head and neck cancer. One possible explanation for the controversial results with TS may be due to the different methods used for determining TS level. Miyamoto et al. [36] reported that TS enzyme activity correlated with neither TS mRNA nor TS protein expression, and they suggested that the discrepancies in the methods used to measure TS must be taken into account when interpreting correlation between TS level and sensitivity to 5-FU. Thus, the role of TS in the antitumor effect of 5-FU is still an unsolved problem and should be further investigated. The biologic relevance of TS is related not only to the importance of this enzyme as a chemotherapeutic target but also to its importance as a DNA synthetic enzyme associated with cell division and proliferation. Johnston et al. [7] demonstrated that TS was an important independent prognostic factor in patients with rectal cancer. In the present study, we obtained a significant correlation between TS activity and venous invasion, suggesting that tumors with high TS activity have more aggressive properties. Furthermore, TS, as well as other prognostic factors, was selected as an independent prognostic factor in gastric cancer. These results indicate that TS plays an important role in the tumor progression of gastric cancer. However, as this result was obtained from a retrospective analysis with a small sample size, the significance of TS as a prognositic factor in gastric cancer should be confirmed by a prospective trial with a larger sample size.
TP is well known to have a high homology with PD-ECGF and to show angiogenesis-inducing activity [8] . Studies on gastric cancer report that TP expression closely correlates with tumor invasion, hematogenous metastasis, lymph node metastasis, venous invasion, lymphatic invasion, and microvascular density [9] [10] [11] 37] . We have also previously reported that TP expression level was significantly higher in tumor tissue than in normal tissue and that TP protein level in tumor correlated with tumor invasion and vessel invasions [23] . The results of the present study reproducibly showed significantly high TP expression in tumors with deeper tumor invasion and the presence of lymphatic and venous invasion, suggesting that TP may be an angiogenesis-inducing factor in gastric cancer.
It is known that TP has activities not only as an angiogenesis-inducing factor but also as a metabolic enzyme for fluoropyrimidines. Capecitabine, an analogue of 5-FU, and 5Ј-DFUR are finally metabolized to 5-FU by TP [14] . A correlation between TP expression and 5Ј-DFUR efficacy has also been shown clinically [17] . Furthermore, TP is also known as one of the phosphorylating enzymes of 5-FU; it phosphorylates 5-FU to 5-fluorodeoxyuridine, which is, in turn, phosphorylated to FdUMP by thymidine kinase. Therefore, there is a possibility that TP has a potential role as an activating enzyme of 5-FU. However, there was no correlation between TP level and sensitivity to 5-FU in the present study. It is well known that orotate phosphoribosyl transferase (OPRT) is the major enzyme in the phos- in human gastric cancer xenografts. 5-FU was administered intraperitoneally at a dose of 50 mg/kg three times every 4 days. S-1 and UFT were administered orally at a dose of 10 mg/kg or 24 mg/kg, respectively, once daily for 9 consecutive days phorylation pathway of 5-FU. Thus, the role of TP in 5-FU sensitivity is considered to be very limited.
In the present study on postoperative survival, there was no significant difference in survival periods according to TP protein expression levels. There are many other studies on the prognostic significance of TP in gastric cancer patients. For example, Maeda et al. [10] reported that TP was a prognostic factor in gastric cancer patients. On the contrary, Tanigawa et al. [11] reported that, although TP expression showed a relationship to microvascular density and hematogenous metastasis, no difference was seen in prognosis according to TP expression level. Thus, the prognostic significance of TP expression in gastric cancer patients is still unclear.
More than 80% of injected 5-FU is catabolized by DPD, mainly in the liver [18] . In patients with DPD deficiency, life-threatening toxicity was observed after 5-FU administration [20] . In addition to the role of DPD in 5-FU toxicity, DPD activity may be a potential factor for controlling 5-FU responsiveness at the tumor site. A high level of tumor DPD would metabolize 5-FU to inactive products before cytotoxic nucleotides could be formed. The correlation between DPD activity and sensitivity to 5-FU was clearly demonstrated by using cancer cell lines [3] , nude mouse xenografts [38] , and human tumors [21, 39] . Several investigators have reported that DPD activity was more strongly correlated than TS activity with sensitivity to 5-FU, both preclinically and clinically [3, 21, 22, 33, 38] . In the present study, we also demonstrated that DPD activity was weakly correlated with in-vitro sensitivity to 5-FU. Sensitivity to 5-FU was observed only in tumors with low DPD activity.
Little has been reported on the association between tumor DPD activity and clinicopathologic factors. In the present study, no statistically significant correlation was observed between tumor DPD activity and clinicopathologic factors. However, overall survival was significantly worse in patients with high DPD activity than in those with low DPD activity in an analysis of all patients. The difference in survival was more strongly observed in a subgroup analysis of patients who received 5-FU-based adjuvant chemotherapy. On the contrary, in a subgroup analysis of patients who did not receive adjuvant chemotherapy, there was no difference in survival according to DPD activity. In addition, DPD was not selected as a prognostic factor in gastric cancer. Therefore, it is suggested that DPD plays a role not in the progression of gastric cancer but in regulating sensitivity to 5-FU.
From these results, DPD is considered to be a most important enzyme which regulates tumor sensitivity to 5-FU. Therefore, attempts have been made to obtain superior antitumor activity in 5-U based chemotherapy by inhibiting DPD activity. Several oral fluoropyrimidine derivatives combined with DPD inhibitory agents have been developed [40] [41] [42] [43] . UFT is a combination drug consisting of 1M tegafur and 4 M uracil. Uracil selectively inhibits the degradation of 5-FU, which is converted from tegafur, by DPD [40, 44, 45] . Because the phosphorylation pathway is not inhibited by uracil, a higher plasma 5-FU level and superior antitumor effect was observed with a lower administration dosage of UFT than for tegafur alone. The clinical efficacy of UFT has been confirmed not only in Japan but also in Western countries [46, 47] . To further promote the DPD inhibitory fluoropyrimidine concept, S-1 has been developed [43, 48] . S-1 consists of 1M tegafur, 0.4M 5-chloro-2,4-dihydroxypyridine (CDHP), and 1M potassium oxonate (Oxo). CDHP is a potent inhibitor of DPD, and is about 200 times more effective than uracil in the inhibition of DPD in vitro [49] . Oxo is a potent inhibitor of OPRT, an enzyme responsible for the metabolic activation of 5-FU. It has been reported that OPRT inhibition occurs mainly in the normal gastrointestinal (GI) tract because of the selective distribution of Oxo in GI tissues [50] . Thus, Oxo selectively inhibits GI toxicity without reducing antitumor activity. Excellent antitumor activity of S-1 has been reported for advanced gastric cancer in a phase II study [51, 52] .
Explanations of the notable antitumor effect of S-1 from the pharmacokinetic point of view have been reported in a rodent model and clinically [26, 53] ; however, the effect of S-1 in respect of degradation or phosphorylation pathways in the tumor has not been demonstrated. In the present study, the role of tumor DPD and TS activity in tumor sensitivity to S-1 was investigated. It is suggested that tumor DPD activity is a good marker for predicting enhanced cytotoxicity and the mechanism of action in S-1 treatment. In tumors with low DPD activity, inhibition of DPD did not bring about increased cytotoxicity, even if tumor DPD activity was further reduced. On the other hand, a significant increase in antitumor effect is expected with S-1 in tumors with high DPD activity. Tumor TS activity may provide further useful information on which pathway, DNA inhibition or RNA disfunction, is predominantly affected after S-1 treatment. In order to further clarify the detailed mechanism of action of S-1, investigation of other phosphorylation enzymes, such as OPRT, ribonucleotide reductase (RNR), and TP may provide useful information [54] .
From the results of the present study and several published reports, the selection of fluoropyrimidines according to TS and DPD activities in the tumor appears to be possible. In tumors with low TS and low DPD activities, there is no need for a DPD inhibitor. Thus, 5-FU alone or in combination with leucovorin, to enhance TS-mediated cytotoxicity, is recommended. In tumors with low TS but high DPD activity, a DPD inhibitory fluoropyrimidine such as S-1 is strongly recommended. On the contrary, in tumors with high TS but low DPD activity, bolus infusion of 5-FU may be recommended, based on the hypothesis of the RNAmediated cytotoxicity of bolus 5-FU infusion. In tumors with high TS and high DPD activities, one possible treatment is suggested to be the combined use of a DPD inhibitor and bolus 5-FU administration, otherwise, the use of fluoropyrimidines is not recommended. Agents that do not demonstrate cross-resistance to 5-FU, such as camptothecines or taxanes, may be recommended.
Recently, a more detailed procedure, in which the precise amount of mRNA expression is determined by using a real-time reverse transcription-polymerase chain reaction assay, has been developed for evaluating the mRNA expression of these enzymes [25] . With this technique, we can predict tumor sensitivity to 5-FU using a minute amount of a biopsy specimen, and we can establish a tailor-made treatment for gastric cancer patients.
